Hot immunological topics in HIV infection

Journal of AIDS and Clinical Research

Volumn 2, Issue 2, 2011, Pages

  Pineda, Juan A ^a   Alcamí, José ^b   Blanco, José R ^c   Blanco, Julià ^d   Boix, Vicente ^e   Casado, José L ^f   López Bernaldo de Quirós, Juan C ^g   Llibre, Josep M ^h  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL SAN PEDRO   (Spain)

^d IrsiCaixa Foundation   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

AIDS; Atherosclerosis; CCR5 inhibitors; CD4+ cells; Hepatitis C virus; HIV

Indexed keywords

EID: 84857184976     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000118     Document Type: Review

References (95)

1. Hogg R, Lima V, Estrellas JA, Grabar S, Battegay M, et al. (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
2. Gazzola L, Tincati C, Bellistrì GM, Monforte A, Marchetti G (2009) The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: Clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 48: 328-337.
3. MacArthur RD, Novak RM (2008) Reviews of anti-infective agents: Maraviroc: The first of a new class of antiretroviral agents. Clin Infect Dis 47: 236-241.
4. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, et al. (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359:1429-1441.
5. Asmuth D, Goodrich J, Cooper D, Haubrich R, Rajicic N, et al. (2008) CD4+ cell restoration after 48 weeks in the Maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 54: 394-397.
6. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, et al. (2004) Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761-770.
7. Mehandru S, Poles MA, Tenner-Racz K, Manuelli V, Jean-Pierre P, et al. (2007) Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol 81: 599-612.
8. Zhou Y, Shen L, Yang HC, Siliciano RF (2008) Preferential cytolysis of peripheral memory CD4+ T cells by in vitro X4-tropic human immunodeficiency virus type 1 infection before the completion of reverse transcription. J Virol 82: 9154-9163.
9. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, et al. (1995) Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes. Nat Med 1: 129-134.
10. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature 417: 95-98.
11. Brenchley JM, Ruff LE, Casazza JP, Koup RA, Price DA, et al. (2006) Preferential infection shortens the life span of human immunodeficiency virusspecific CD4+ T cells in vivo. J Virol 80: 6801-6809.
12. Goonetilleke N, Liu MKP, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206: 1253-1272.
13. Wan YY (2010) Multi-tasking of helper T cells. Immunology 130: 166-171.
14. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
15. Deayton JR, Sabin CA, Johnson MA, Emery VC, Wilson P, et al. (2004) Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363: 2116-2121.
16. Fahey JL, Taylor JM, Manna B, Nishanian P, Aziz N, et al. (1998) Prognostic significance of plasma markers of immune activation, HIV viral load and CD4+T-cell measurements. AIDS 12: 1581-1590.
17. Jaworowsi A, Crowe SM (1999) Does HIV cause depletion of CD4+ T cells in vivo by the induction of apoptosis?. Immunol Cell Biol 77: 90-98.
18. Peakman M, Mahalingam M, Pozniak A, McManus TJ, Phillips AN, et al. (1995) Markers of immune cell activation and disease progression. Cell activation in HIV disease. Adv Exp Med Biol 374: 17-26.
19. Bürgisser P, Hammann C, Kaufmann D, Battegay M, Rutschmann OT (1999) Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. Clin Exp Immunol 115: 458-463.
20. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H (2003) Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS 17: 521-530.
21. Altfeld M, Addo MM, Kreuzer KA, Rockstroh JK, Dumoulin FL et al. (2000) T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. J Acquir Immune Defic Syndr 23:287-294.
22. Savarino A, Bottarel F, Malavasi F, Dianzani U (2000) Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions?. AIDS 14: 1079-1089.
23. Mothe B, Ibarrondo J, Llano A, Brander C (2009) Virological, immune and host genetics markers in the control of HIV infection. Disease Marker 27: 105-120.
24. Gurunathan S, Habib RE, Baglyos L, Meric C, Plotkin S, et al. (2009) Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 27: 1997-2015.
25. Appay V, Sauce D (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214: 231-241.
26. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
27. Kanwar B, Favre D, McCune JM (2010) Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 5: 151-157.
28. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517.
29. Sempere JM, Soriano V, Benito JM (2007) T regulatory cells and HIV infection. AIDS Rev 9: 54-60.
30. Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, et al. (2010) HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS 24: 491-502.
31. Autran B, Carcelaint G, Li TS, Gorochov G, Blanc C, et al. (1999) Restoration of the immune system with anti-retroviral therapy. Immunol Lett 66: 207-211.
32. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, et al. (1998) Long-lasting recovery in CD4+T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351: 1682-1686.
33. Chen S, Tuttle DL, Oshier JT, Knot HJ, Streit WJ, et al. (2005) Transforming growth factor-beta1 increases CXCR4 expression, stromal-derived factor-1alpha-stimulated signalling and human immunodeficiency virus-1 entry in human monocyte-derived macrophages. Immunology 114: 565-574.
34. Burton CT, Goodall RL, Samri A, Autran B, Kelleher AD, et al. (2008) Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: An INITIO substudy. Clin Exp Immunol 152: 252-257.
35. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California, USA. Abstract 527.
36. Revised DHHS Guidelines issues (2008) AIDS Pat Car STD 22: 1021.
37. Aiuti F, Mezzaroma I (2006) Failure to reconstitute CD4+ T cells despite suppression of HIV replication under HAART. AIDS Rev 8: 88-97.
38. Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, et al. (2005) Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 191: 1670-1679.
39. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, et al. (2006) Comparative analysis of T-cell turnover and homeostatic parameters in HIVinfected patients with discordant immune-virological responses to HAART. AIDS 20: 1727-1736.
40. Massanella M, Negredo E, Pérez-Alvarez N, Puig J, Ruiz-Hernández R, et al. (2010) CD4+T-cell hyperactivation and susceptibility to cell death determine poor CD4+T-cell recovery during suppressive HAART. AIDS 24: 959-968.
41. Molina-Pinelo S, Vallejo A, Díaz L, Soriano-Sarabia N, Ferrando-Martínez S, et al. (2009) Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4+T cell repopulation. J Antimicrob Chemother 64:579-588.
42. Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, et al. (2010) Nadir CD4+T cell count as predictor and high CD4+T cell intrinsic apoptosis as final mechanism of poor CD4+T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 50: 1300-1308.
43. Marchetti G, Bellistrì GM, Borghi E, Tincati C, Ferramosca S, et al. (2008) Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22: 2035-2038.
44. Riddler SA, Haubrich R, DiRienzo G, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV infection. N Engl J Med 358: 2095-2106.
45. Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, et al. (2009) A double-blind, placebo-controlled trial of Maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 199:1638-1647.
46. Asmuth DM, Goodrich J, Cooper DA, Haubrich R, Rajicic N, et al. (2010) CD4+ T-cell restoration after 48 weeks in the Maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 54: 394-397.
47. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California. Abstract 285.
48. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, et al. (2009) Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 119: 997-1007.
49. D'Egidio GE, Kravcik S, Cooper DL, Cameron DW, Ferguson DA, et al. (2007) Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T cell count < 200 cells/ml when viral replication is suppressed. AIDS 21: 1711-1715.
50. Taiwo Bo, Li X, Palella F, Jacobson LP, Margolick JB, et al. (2009) Higher risk of AIDS or death in patients with lower CD4+ cell counts after virally suppressive HAART. HIV Med 10: 657-660.
51. Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, et al. (2008) Clinical outcome of antiretroviral naive HIV infected patients with discordant immunological and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47: 553-558.
52. Buchacz K, Baker RK, Palella FJ, Chmiel JS, Lichtenstein KA, et al. (2010) AIDS defining opportunistic illnesses in US patients: 1994-2007: A cohort study. AIDS 24: 1549-1554.
53. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, et al. (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23: 41-50.
54. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370: 59-67.
55. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC (2009) Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 52: 203-208.
56. Bedimo R (2008) Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep 5: 140-149.
57. Nyagol J, Leucci E, Onnis A, De Falco G, Tigli C, et al. (2006) The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther 5: 684-690.
58. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California, USA. Abstract 429.
59. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2005) Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 64: 529-536.
60. Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, et al. (2008) Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 47: 544-552.
61. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California, USA. Abstract 172.
62. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California, USA. Abstract 484b.
63. Brenner DA (2009) Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 120: 361-368.
64. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P (2010) Viral hepatitis and HIV-coinfection. Antivir Res 85: 303-315.
65. Macías J, Castellano V, Merchante N, Palacios RB, Mira JA, et al. (2004) Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18: 767-774.
66. Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, et al. (2006) Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20: 49-57.
67. Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, et al. (2007) Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46: 622-630.
68. Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, et al. (2010) Gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 59: 513-520.
69. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, et al. (2008) HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 134: 803-811.
70. Jiménez A, Molero L, Jiménez A, Castañón S, Subirá D, et al. (2002) Role of antiretroviral regimes in HIV-1 patients in reducing immune activation. Immunology 106: 80-86.
71. Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, et al. (2005) The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41: 123-131.
72. Macías J, Berenguer J, Japon MA, Girón JA, Rivero A, et al. (2009) Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 50: 1056-1063.
73. Calza L, Pocaterra D, Pavoni M, Colangeli V, Manfredi R, et al. (2009) Plasma levels of VCAM-1, ICAM-1, Eselectin, and P-selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. J Acquir Immune Defic Syndr 50: 430-432.
74. De Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R (2004) HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet 4: 213-222.
75. Monsuez JJ, Charniot JC, Escaut L, Teicher E, Wyplosz B, et al. (2009) HIVassociated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol 133: 293-306.
76. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ (2008) Major clinical outcomes in antiretroviral therapy (ART)-nai{dotless}ve participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197: 1133-1144.
77. Mastroianni CM, Lichtner M, Mengoni F, D́Agostino C, d́Ettorre G, et al. (2000) Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients. Clin Immunol 95: 212-217.
78. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, et al. (2009) Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 49: 1119-1127.
79. Neuhaus J, Jacobs Jr DR, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection. J Infect Dis 201:1788-1795.
80. Harris TB, Ferrucci L, Tracy RP, Corti MC, Cohen HJ, et al. (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106: 506-512.
81. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, et al. (2008) Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5: e78.
82. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, et al. (2007) Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke. The Edinburgh Artery Study. Circulation 115: 2119-2127.
83. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, et al. (2001) Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103: 2323-2327.
84. Friis Moller N, Reiss O, Sabin CA, Weber R, Monforte A, et al. (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356: 1723-1735.
85. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M (2002) Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 185: 456-462.
86. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California, USA. Abstract 54LB.
87. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, et al. (2010) Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 201: 803-813.
88. Sax PE (2010) Maraviroc for treatment-naive patients with HIV-1 infection: Is the glass half empty or half full? J Infect Dis 201:797-799.
89. Llibre JM, Schapiro JM, Clotet B (2010) Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 50: 872-881.
90. Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, et al. (2009) When and how to use maraviroc in HIV-infected patients. AIDS 23: 2377-2385.
91. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California, USA. Abstract 92.
92. th Conference on Retrovirus and Opportunistic Infections. San Francisco, California, USA. Abstract 646.
93. th International AIDS Conference. Cape Town, South Africa. Abstract MOPEB040.
94. Wilkin T, Ribaudo H, Gulick RM (2010) The relationship of CCR5 inhibitors to CD4+cell count changes: A meta-analysis of recent clinical trials. 15th Retroconference on Retroviruses and Opportunistic Infections. Boston, Masachusets, USA. Abstract 800.
95. Zolopa A, Andersen J, Powderly W, Sánchez A, Sanne I, et al. (2009) Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 4: e5575.